2,3800 -0,08 (-3,25%)
Before hours: 8:43AM EST
|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Adam S. Grossman||Co-Founder, Pres, CEO & Director||941,16k||N/D||1977|
|Dr. Jerrold B. Grossman Ph.D., D.P.S.||Co-Founder & Vice Chairman||70,9k||N/D||1948|
|Mr. Brian Lenz CPA, CPA||Exec. VP & CFO||741,73k||N/D||1972|
|Dr. James Mond||Exec. VP, Chief Scientific Officer & Chief Medical Officer||856,99k||N/D||1946|
|Ms. Kim Tripodo||Exec. Director & Head of Human Resource and Admin. Operations||N/D||N/D||N/D|
|Mr. Skyler Bloom||Director of Investor Relations & Corp. Strategy||N/D||N/D||N/D|
|Ms. Kaitlin Kestenberg||VP of Compliance, Project Management & Clinical Operations||N/D||N/D||N/D|
|Mr. Michael Least||VP of Sales & Commercial Operations||N/D||N/D||N/D|
|Mr. Drew Pantello||VP of Marketing & Corp. Devel.||N/D||N/D||N/D|
|Dr. Gene A. Wetzstein BCOP, Pharm.D.||Exec. Director & Head of Scientific Engagement||N/D||N/D||N/D|
ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
L'ISS Governance QualityScore di ADMA Biologics, Inc. al 22 gennaio 2021 è 7. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 6; diritti degli azionisti: 8; retribuzione: 8.